908 Devices (NASDAQ:MASS) Posts Earnings Results, Beats Expectations By $0.04 EPS

908 Devices (NASDAQ:MASS) issued its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. The company had revenue of $18.95 million for the quarter, compared to the consensus estimate of $18.31 million.

Here are the key takeaways from 908 Devices’ conference call:

• Revenue growth accelerated and guidance increased: Q3 revenue rose 35% year over year to a record $19 million, and the company raised the low end of its 2026 revenue outlook to $68.5 million–$70 million, implying 22%–25% annual growth.
• Device adoption broadened, including internationally: 908 Devices shipped a record 300-plus devices, bringing its installed base to about 4,400; international customers accounted for 40% of Q3 revenue, supported by ProtectIR government wins and other platform demand.
• NIRLab showed early commercial traction: The company sold about 100 devices in the quarter, while platform scans surpassed 1 million cumulatively. Management sees subscriptions and broader connected services as a potential source of recurring revenue, though the business is still developing.
• Profitability improved modestly, while future growth depends on execution: Adjusted EBITDA loss was $1.7 million, and the company ended Q3 with $99.1 million in cash and no debt. Management cited the next-generation MX908 and potential 2027 AVCAD orders as growth drivers, but AVCAD revenue is excluded from 2026 guidance and reaching the upper end of the outlook depends on closing key Q4 opportunities.

908 Devices Stock Performance

Shares of MASS stock traded up $0.49 during mid-day trading on Wednesday, reaching $10.47. 142,508 shares of the company’s stock traded hands, compared to its average volume of 339,866. 908 Devices has a 12 month low of $5.03 and a 12 month high of $13.35. The firm has a 50 day moving average price of $11.19 and a two-hundred day moving average price of $8.51. The firm has a market capitalization of $432.64 million, a PE ratio of -11.00 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group started coverage on 908 Devices in a report on Thursday, September 10th. They set a “buy” rating and a $13.50 price target on the stock. Stifel Nicolaus lifted their price objective on 908 Devices from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, November 4th. Roth Capital upped their price objective on 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen downgraded 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Key 908 Devices News

Here’s some of the latest news about MASS:

• Positive Sentiment: Stifel Nicolaus raised its price target to $14 from $12 and maintained a Buy rating. The new target implies about 40% upside from the cited $9.98 share price, signaling increased analyst optimism. Stifel Nicolaus stock recommendations
• Positive Sentiment: Q3 revenue rose 35% year over year to a record $18.95 million, helped by record device shipments. Revenue topped the $18.31 million consensus estimate, while the loss of $0.11 per share was narrower than analysts’ expected $0.15 loss. 908 Devices Q3 2026 results
• Negative Sentiment: 908 Devices remains unprofitable: it reported a quarterly loss, and its net margin and return on equity were negative. The EPS loss was also wider than the $0.15 loss recorded a year earlier, despite beating the current-quarter estimate.

Insider Transactions at 908 Devices

In related news, CFO Joseph Griffith, IV sold 5,000 shares of 908 Devices stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $13.03, for a total transaction of $65,150.00. Following the transaction, the chief financial officer directly owned 116,497 shares in the company, valued at approximately $1,517,955.91. The trade was a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher D. Brown sold 30,000 shares of 908 Devices stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $10.95, for a total value of $328,500.00. Following the transaction, the director owned 775,559 shares in the company, valued at $8,492,371.05. This trade represents a 3.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 134,115 shares of company stock worth $1,473,296 in the last three months. Corporate insiders own 28.20% of the company’s stock.

908 Devices Company Profile

908 Devices Inc. is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions. The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.